A multicenter, open-label, multiple-dose Phase Ib/II study evaluating the safety and tolerability of CS3008 (BLU-554) in combination with CS1001 in subjects with locally advanced or metastatic hepatocellular carcinoma (HCC) Research
Research Square (Research Square)